- ISSN 1672-5069
- CN 34-1270/R
- CODEN SGZHBF
Journal of Practical Hepatology ›› 2025, Vol. 28 ›› Issue (5): 641-647.doi: 10.3969/j.issn.1672-5069.2025.05.001
Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association
Received:2025-05-30
Online:2025-09-10
Published:2025-09-19
Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version)[J]. Journal of Practical Hepatology, 2025, 28(5): 641-647.
| [1] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol, 2023, 79(2): 516-537. [2] Mak LY, Liu K, Chirapongsathorn S, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol, 2024, 21( 12): 834-851. [3] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol, 2019, 71( 1):212-221. [4] Br VK, Sarin SK. Acute-on-chronic liver failure: terminology, mechanisms and management. Clin Mol Hepatol, 2023, 29(3):670-689. [5] Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut, 2022, 71( 1): 148-155. [6] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南. 中华肝脏病杂志, 2006, 14(9):643-646. [7] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学 会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南 (2012 年 版). 中 华 肝 脏 病 杂 志 , 2013, 21(3): 177-183. [8] 中华医学会感染病学分会肝衰竭与人工肝学组 , 中华医 学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指 南 (2018 年 版). 中 华 临 床 感 染 病 杂 志 , 2018, 11(6): 401-410. [9] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学 会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南 (2024 年 版). 中 华 肝 脏 病 杂 志 , 2025, 33( 1): 18-33. [10] Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association forthe study of the liver (APASL). Hepatol Int,2009, 3( 1):269-282. [11] Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int, 2014, 8(4): 453-471. [12] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019, 13(4): 353-390. [13] Choudhury A, Kulkarni AV, Arora V, et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int, 2025, 19( 1): 1-69. [14] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol, 2023, 79(2):461-491. [15] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60(1): 250-256. [16] Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67(12): 2181-2191. [17] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926. [18] Ohnishi H, Sugihara J, Moriwaki H, et al. Acute-on-chronic liver failure. Ryoikibetsu Shokogun Shirizu, 1995, (7): 217-219. [19] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144(7): 1426-1437, 1437,e1-9. [20] Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology, 2014, 147(1):4-10. [21] Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol, 2022, 117(2):225-252. [22] Karvellas CJ, Bajaj JS, Kamath PS, et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology, 2024, 79(6): 1463-1502. [23] 徐曼曼, 李珊珊, 杨颜榕, 等. 2012 至 2021 年北京佑安医院 肝衰竭住院患者流行病学特征. 中华肝脏病杂志, 2024, 32( 1):49-57. [24] Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis, 2022, 122:476-485. [25] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology, 2023, 165(4): 1025-1040. [26] Li H, Xia Q, Zeng B, et al. Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J Hepatol, 2015, 63(1):50-59. [27] Baloda V, Anand A, Yadav R, et al. Histologic changes in core-needle liver biopsies from patients with acute-on-chronic liver failure and independent histologic predictors of 28-day mortality. Arch Pathol Lab Med, 2022, 146(7):846-854. [28] Rastogi A, Maiwall R, Bihari C, et al. Two-tier regenerative response in liver failure in humans. Virchows Arch, 2014, 464(5):565-573. [29] Xu M, Chen Y. New perspectives in the definition and classification of acute-on-chronic liver failure. Chin Med J (Engl), 2024, 137(21):2521-2525. [30] Xu M, Kong M, Yu P, et al. Acute-on-chronic liver failure defined by Asian Pacific Association for the Study of the Liver should include decompensated cirrhosis. Front Med (Lausanne), 2021, 8:750061. [31] Yuan H, Cao Y, Yu Z, et al. Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis. BMC Gastroenterol, 2023, 23( 1):319. [32] Qiu S, Zhang Q, Hu J, et al. Impact of onset time, number, type, and sequence of extrahepatic organ failure on prognosis of acute-on-chronic liver failure. J Clin Transl Hepatol, 2024, 12(3):257-265. [33] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33(2):464-470. [34] Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on theliver-transplant waiting list. N Engl J Med, 2008, 359( 10): 1018-1026. [35] Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. HepatolInt, 2017, 11(5):461-471. [36] Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol, 2021, 75(5): 1104-1115. [37] Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liverfailure. J Hepatol, 2014, 61(5): 1038-1047. [38] O'Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67(6):2367-2374. [39] Yu Z, Zhang Y, Li Y, et al. Development of a widely applicable and simple prognostic score for patients with acute-on-chronic liver failure. J Clin Transl Hepatol, 2022, 10(5):867-878. [40] Yu Z, Zhang Y, Cao Y, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators. Sci Rep, 2021, 11(1): 1810. [41] Xu MM, Kong M, Yu PF, et al. Clinical course and outcome patterns of acute-on-chronic liver failure: a multicenter retrospective cohort study. J Clin Transl Hepatol, 2021, 9(5):626-634. [42] Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology, 2017, 65(3): 1044-1057. [43] Iwasa M, Iwata K, Hara N, et al. Nutrition therapy using a multidisciplinary team improves survival rates inpatients with liver cirrhosis. Nutrition, 2013, 29( 11-12): 1418-1421. D [44] 中华医学会肝病学分会,中华医学会消化病学分会.终末期肝病临床营养指南.中华肝脏病杂志,2019,27(5):330-342. [45] Liu X, Kong M, Hua X, et al. Effects of an individualized nutritional intervention on the prognosis of patients with liver failure. Asia Pac J Clin Nutr, 2022, 31(2): 215-221. [46] Liu X, Kong M, Hua X, et al. Effects of an individualized nutrition intervention on the respiratory quotient ofpatients with liver failure. Asia Pac J Clin Nutr, 2019, 28(3): 428-434. [47] Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol, 2012, 27(3): 430-441. [48] Vaisman N, Katzman H, Carmiel-Haggai M, et al. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr, 2010, 92(1): 137-140. [49] Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology, 2008, 48(2): 557-566. [50] 张思琪, 陈慧娜, 耿楠, 等. 肌少症与新型慢加急性肝衰竭 5 种临床分型的关系. 西南医科大学学报 , 2024, 47( 1): 51-57. [51] Geng N, Kong M, Zhang J, et al. Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure. Sci Rep, 2024, 14(1): 13609. [52] Geng N, Kong M, Chen H, et al. Muscle function is superior to muscle mass in predicting 90-day mortality in patients with acute-on-chronic liver failure: a prospective study. Nutrition, 2024, 118:112290. [53] Levine M, Stellpflug SJ, Pizon AF, et al. Hypoglycemia and lactic acidosis outperform King's College criteria for predicting death or transplantin acetaminophen toxic patients. Clin Toxicol (Phila), 2018, 56(7):622-625. [54] Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res, 1993, 98:69-74. [55] 周文兴, 吕国良. 异甘草酸镁治疗慢加急性肝衰竭患者疗效观察. 中国医药, 2012, 7(8): 1046. [56] 刘潇聪, 陈耀凯, 李晖, 等. 复方甘草酸苷对重型肝炎的治 疗作用及机制研究. 第三军医大学学报 , 2009, 31( 18): 1806-1808. [57] 毛海鹰, 滕华安, 廖礼艳, 等. 异甘草酸镁治疗重型肝炎肝 衰竭疗效的 Meta 分析. 中国肝脏病杂志(电子版),2017, 9( 1): 15-19. [58] Ye C, Li W, Li L, et al. Glucocorticoid treatment strategies in liver failure. Front Immunol, 2022, 13:846091. [59] Jia L, Xue R, Zhu Y, et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. BMC Med, 2020, 18(1):383. [60] Xu Y, Jiang Y, Li Y. Outcomes of glucocorticoid treatment in HBV-associated acute-on-chronic liver failure patients: a retrospective observational study. Turk J Gastroenterol, 2021, 32(5):473-480. [61] Zhe-Bin W, Ke W, Mo ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101505. [62] Shi P, Zhu WT, Liang A, et al. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure. Acta Gastroenterol Belg, 2022, 85(4):593-600. [63] Chen JF, Chen SR, Lei ZY, et al. Safety and efficacy of thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int, 2022, 16(4): 775-788. [64] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019, 27( 11):846-865. [65] 中华医学会感染病学分会. 终末期肝病合并感染诊治专家 共识(2021 年版). 中华肝脏病杂志, 2022, 30(2): 147-158. [66] 中国研究型医院学会肝病专业委员会重症肝病学组, 中华 医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并 侵袭性真菌感染诊治专家共识. 中华肝脏病杂志, 2022, 30(2): 159-168. [67] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会消化内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南.中华内科杂志,2023,62(1):7-22. [68] 中华医学会肝病学分会.肝硬化腹水诊疗指南(2023年版).中华肝脏病杂志,2023,31(8):813-826. [69] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南(2024年版).中华肝脏病杂志,2024,32(9):799-812. [70] Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. Crit Care Med, 2020, 48(3):e173-e191. [71] Singh SA, Shrivastava P, Agarwal A, et al. LTSI Consensus guidelines: preoperative pulmonary evaluation in adult liver transplant recipients. J Clin Exp Hepatol, 2023, 13(3): 523-531. [72] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenalsyndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(2): 1014-1048. [73] Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review. Gastroenterology, 2024, 166(1): 202-210. [74] 段钟平. 人工肝脏治疗学. 北京:中国医药科技出版社, 2002. [75] 许家璋, 段钟平. 实用人工肝及血液净化操作手册. 北 京: 北京大学出版社, 2010. [76] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019, 34(4): 392-398. [77] Komura T, Taniguchi T, Sakai Y, et al. Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure. J Gastroenterol Hepatol, 2014, 29(4): 782-786. [78] Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care, 2019, 25(2): 187-191. [79] Liu H, Zhang Q, Liu L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Artif Organs, 2020, 44( 10):E434-E447. [80] Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review ofcurrent clinical applications. Ther Apher Dial, 2021, 25(2): 145-151. [81] Maiwall R, Bajpai M, Singh A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial. Clin Gastroenterol Hepatol, 2022, 20(4):e831-e854. [82] 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血 液净化技术临床应用专家共识(2022 年版). 临床肝胆病 杂志, 2022, 38(4):767-775. [83] Xu W, Zhu S, Yang L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure. J Med Virol, 2023, 95(3):e28650. [84] Wang L, Xu W, Zhu S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: a prospective study. J Clin Transl Hepatol, 2023, 11(4):908-917. [85] Ocak I. A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous venovenous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation. Ann Transplant, 2023, 28:e939745. [86] 周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准. 中华肝脏病杂志, 2022, 30(2): 127-130. [87] European Association for the Study of the Liver; Samuel D, De Martin E, et al. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol, 2024, 81(6): 1040-1086. [88] 徐曼曼, 武羽, 李珊珊, 等. 不同预后评分在慢加急性肝衰 竭肝移植决策中的应用. 中华肝脏病杂志 , 2023, 31(6): 574-581. [89] Wu Y, Xu M, Duan B, et al. Acute-on-chronic liver failure: clinical course and liver transplantation. Expert Rev Gastroenterol Hepatol, 2023, 17(3): 251-262. [90] Huebener P, Sterneck MR, Bangert K, et al. Stabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival. Aliment Pharmacol Ther, 2018, 47(11):1502-1510. [91] Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol, 2020, 72(3):481-488. [92] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med, 2012, 1( 10):725-731. [93] Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure:a randomized controlled trial. Hepatology, 2017, 66(1): 209-219. [94] Duan Z, Xin S, Zhang J, et al. Comparison of extracorporeal cellular therapy (ELAD©) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure. Hepat Med, 2018, 10:139-152. [95] Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. Cell Stem Cell, 2023, 30(5): 617-631.e8. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
